PAH-CHD predominantly Lt-Rt shunt with borderline PVR and ES

Conditions

Data of outcomes in patients who had PAH-CHD (confirmed by dignostic cardiac catheterization) with borderline pulmonary vascular resistance (PVR) and recieved directed targeted therapy prior to surgic Pulmonary arterial hypertension, Congenital heart disease, treat and repair

Jantaras Sengsim, Chodchanok Vijarnsorn, Prakul Chanthong, Paweena Chungsomprasong, Supaluck Kanjanauthai et al. (15 authors)

Scientific Reports2024-12-02

10.1038/s41598-024-81834-9

Contemporary survival outcomes of congenital systemic-to-pulmonary shunt in children with borderline pulmonary vascular resistant index compared to Eisenmenger syndrome.

Chaiwangyen N, Vijarnsorn C, Chungsomprasong P, Chanthong P, Kanjanauthai S, Thammasate P, Pacharapakornpong T, Bositthipichet D, Sengsim J, Soongswang J, Tocharoenchok T, Nitiyarom E, Tantiwongkosri K, Subtaweesin T, Durongpisitkul K.

2024-07-231 citations

10.1038/s41598-024-67899-6

Interventions

Patients who had PAH&#45

CHD (confirmed by dignostic cardiac catheterization) with borderline pulmonary vascular resistance and recieved directed targeted grug therapy prior to surgical repair (treat and repair strategy)

Treatment

CHD with borderline PVR

Eligibility

Sex/Gender

All

Age

3 Months to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who underwent cardiac catheterization to assess hemodynamic data or transcatheter closure of the defects in Siriraj Hospital between January 1st, 1995 and December 31st, 2021 2. All patients who had evidence of PAH-CHD on the cardiac catheterization including mPAP >20 mmHg, PAWP < 15 mmHg and calculated PVR > 3 WU based on a current definition of PAH 3. Patients who were classified in Eisenmenger syndrome and PAH-CHD with prevalent left to right shunt

Exclusion criteria

Exclusion criteria: 1. Patients who had age < 3 months, 2. Patients with single ventricle following surgery 3. Patients who were classified in PAH with small defect and PAH following defect correction

Design outcomes

Primary

Measure	Time frame
Survival rate/mortality End of 2023 Survival rate	—

Secondary

Measure	Time frame
WHO Functional class end of 2023 Declined of functional class to III-IV	—

Countries

Thailand

Contacts

Public ContactChodchanok VIjarnsorn

Faculty of Medincine Siriraj Hospital, Mahidol University

cvijarnsorn@yahoo.com66813447015

Outcome results

None listed